Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma

European Journal of Endocrinology

Volumn 136, Issue 1, 1997, Pages 67-73

  Stridsberg, Mats ^a   Husebye, Eystein S ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CATECHOLAMINE; CHROMOGRANIN A; CHROMOGRANIN B; NEUROPEPTIDE Y; NORADRENALIN; PANCREASTATIN;

ADOLESCENT; ADRENALIN URINE LEVEL; ADULT; AGED; ARTICLE; CATECHOLAMINE URINE LEVEL; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NORADRENALIN URINE LEVEL; PHEOCHROMOCYTOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN DETERMINATION; RADIOIMMUNOASSAY;

EID: 0031053835     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1360067     Document Type: Article

References (25)

1. Fonseca V & Bouloux P-M. Phaeochromocytoma and paraganglioma. Baillière's Clinical Endocrinology and Metabolism 1993 7 509-544.
2. Young WF, Jr. Pheochromocytoma: 1926-1993. Trends in Endocrinology and Metabolism 19934 122-127.
3. O'Connor DT & Deftos LJ. Secretion of chromogranin A by peptide-produdng endocrine neoplasms. New England Journal of Medicine 1986 314 1145-1151.
4. Hsiao RJ, Neumann HPH, Farmer RJ, Barbosa JA & O'Connor DT. Chromogranin A in familial pheochromocytoma: Diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. American Journal of Medicine 1990 88 607-613.
5. Hsiao RJ, Farmer RJ, Takiyyuddin MA & O'Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine 1991 70 33-45.
6. Gröndai S, Eriksson B, Hamberger B & Theodorsson E. Plasma chromogranin A+B, neuropeptide Y and catecholamines in pheochromocytoma patients. Journal of Internal Medicine 1991 229 453-456.
7. Mouri T, Sone M, Takahashi K, Itoi K, Totsune K, Hayashi Y, Hasegawa S, Ohneda M, Murakami O & Miura Y. Neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma and neuroblastoma. Clinical Science 1992 83 205-211.
8. Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J, Fonseca E, Ghillani PP, Aubert B, Travagli JP, Gardet P & Parmentier C. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. Journal of Endocrinological Investigation 1992 15 631-642.
9. Tabarin A, Minot AP, Dallochio M, Roger P & Ducassou D. Plasma concentration of neuropeptide Y in patients with adrenal hypertension. Regulatory Peptides 1992 42 51-61.
10. Neumann HPH, Berger DP, Sibmund G, Blum U, Schmidt D, Farmer RJ, Volk B & Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and Von Hippel-Lindau disease. New England Journal of Medicine 1993 329 1531-1538.
11. Canale MP & Bravo EL, Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. Journal of Clinical Endocrinology and Metabolism 1994 78 1139-1144.
12. Boomsma F, Bhaggoe UM, 't Veld AJMI & Schalekamp MADH. Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. Clinica Chimica Acta 1995 239 57-63.
13. Wiedenmann B & Huttner WB. Synaptophysin and chromogranins/secretogranins-widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Archiv 1989 58 95-121.
14. Wiedenmann B, Waldherr R, Buhr H, Hille A, Rosa P & Huttner WB. Identification of gastroenteropancreatic neuroendocrine cells in normal and neoplastic human tissue with antibodies against synaptophysin, chromogranin A, secretogranin I (chromogranin B), and secretogranin II. Gastroenteroloay 1988 95 1364-1374.
15. Winkler H & Fischer-Colbrie R. The chromogranins A and B: The first 25 years and future perspectives. Neuroscience 1992 49 497-528.
16. Iacangelo AL, Fischer Colbrie R, Koller KJ, Brownstein MJ & Eiden LE. The sequence of porcine chromogranin A messenger RNA demonstrates chromogranin A can serve as the precursor for the biologically active hormone, pancreastatin. Endocrinology 1988 122 2339-2341.
17. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ & Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986 324 476-478.
18. Stridsberg M, Hellman U, Wilander E, Lundqvist G, Hellsing K & Öberg K. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: Development of a specific radioimmunoassay for chromogranin A and its fragments. Journal of Endocrinology 1993 139 329-337.
19. Stridsberg M, Öberg K, Li Q, Engström U & Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. Journal of Endocrinology 1995 144 49-59.
20. Stridsberg M & Lundqvist G. Radioimmunoassay of neuropeptide Y (NPY) in biological fluids. Circulating levels depend on renal function. Clinica Chimica Acta 1989 185 61-72.
21. Schober M, Fischer Colbrie R, Schmid KW, Bussolati G, O'Connor DT & Winkler H. Comparison of chromogranins A, B, and secretogranin II in human adrenal medulla and pheochromocytoma. Laboratory Investigation 1987 57 385-391.
22. Hsiao RJ, Seeger RC, Yu AL & O'Connor DT. Chromogranin A in children with neuroblastoma: Serum concentration parallels disease stage and predicts survival. Journal of Clinical Investigation 1990 85 1555-1559.
23. Curry WJ, Johnston CF, Shaw C & Buchanan KD. Distribution and partial characterisation of immunoreactivity to the putative C-terminus of rat pancreastatin. Regulatory Peptides 1990 30 207-219.
24. Borglum Jensen TD, Holst JJ & Fahrenkrug J. Characterization of immunoreactive pancreastatin in porcine tissues. Scandinavian Journal of Clinical Laboratory Investigation 1991 51 681-691.
25. Hagn C, Schmid KW, Fischer Colbrie R & Winkler H. Chromogranin A, B, and C in human adrenal medulla and endocrine tissues. Laboratory Investigation 1986 55 405-411.